AAM
BBIO icon

Alphadyne Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Alphadyne Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$520K Buy
+7,000
New +$507K 0.01% 683

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Alphadyne Asset Management's BBIO Position: Q1 2026 in Review

Alphadyne Asset Management opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 1,014 shares worth $75.3K. The stake represents ﹤0.01% of the portfolio and ranks #851 among its holdings.

457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Alphadyne Asset Management held 1,014 shares of BridgeBio Pharma worth $75.3K as of Q1 2026.
  • BridgeBio Pharma was a new Alphadyne Asset Management position in Q1 2026.
  • BridgeBio Pharma made up ﹤0.01% of Alphadyne Asset Management's portfolio in Q1 2026, its #851 holding.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Alphadyne Asset Management's 13F filing for Q1 2026, filed 15 May 2026.